国际医药卫生导报2014，Vol.20Issue(22)：3444-3446,3.DOI:10.3760/cma.j.issn.1007-1245.2014.22.027
尤瑞克林联合依达拉奉治疗急性脑梗死的临床观察
Urinary kallidinogenase in combination with edaravone for acute cerebral infarction
摘要
Abstract
Objective To evaluate the efficacy and safety of urinary kallidinogenase combined with edaravone for acute cerebral infarction.Methods 95 patients with acute cerebral infarction were randomly divided into a treatment group and a control group.The control group were treated with edaravone and basical drugs; in addition,the treatment group were treated with urinary kallidinogenase.The treatment course was 14 days.The National Institutes of Health Stroke Scale (NIHSS),Barthel Index score,and clinical efficacies were observed before and after the treatment in both groups.At the same time,the drug adverse reactions were observed.Results The NIHSS and BI score were improved in both groups.However,the NIHSS,BI score,and total efficacy were better in the treatment group than in the control group.Conclusions Urinary kallidinogenase combined with edaravone for acute cerebral infarction is effective,safe,and worth being clinically generalized.关键词
尤瑞克林/依达拉奉/急性脑梗死Key words
Urinary kallidinogenase/ Edaravone/ Acute cerebral infarction引用本文复制引用
孙丽霞..尤瑞克林联合依达拉奉治疗急性脑梗死的临床观察[J].国际医药卫生导报,2014,20(22):3444-3446,3.
